Until now, measurements of Aβ1-42, total tau and p-tau181 in CSF are the best molecular markers for the early diagnosis of AD, although the relative invasiveness of CSF collection over drawing blood is a major limit in measuring CSF AD biomarkers [125,126,127]. This evidence concerns the gene MAPT and Alzheimer disease.